Bright Minds Biosciences Inc (DRUG) — Cash Flow-to-Debt Ratio
Bright Minds Biosciences Inc (DRUG) has a Cash Flow-to-Debt Ratio of -2.48x as of March 2026, meaning its operating cash flow of $-9.50 Million could theoretically repay -2% of its total liabilities ($3.83 Million) in one year. Check DRUG cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Bright Minds Biosciences Inc Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Bright Minds Biosciences Inc across 7 annual periods. Also explore Bright Minds Biosciences Inc total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Bright Minds Biosciences Inc (2019–2025)
Year-by-year debt coverage analysis for Bright Minds Biosciences Inc. For market capitalisation and broader financial context, see market cap of Bright Minds Biosciences Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.66x | $-8.69 Million | $2.38 Million | ▼ -12.3% |
| 2024 | -3.26x | $-1.85 Million | $568.26K | ▲ +87.0% |
| 2023 | -25.01x | $-7.02 Million | $280.86K | ▼ -184.3% |
| 2022 | -8.80x | $-13.59 Million | $1.54 Million | ▲ +23.2% |
| 2021 | -11.46x | $-7.32 Million | $638.57K | ▼ -499.8% |
| 2020 | -1.91x | $-288.39K | $150.92K | ▼ -67.0% |
| 2019 | -1.14x | $-42.01K | $36.71K | — |